Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Breast Cancer SurgeryNeoadjuvant TherapySentinel Lymph Node Biopsy (SLNB)
Interventions
DRUG

carbon suspension

Before primary systemic therapy, a core needle biopsy or fine-needle aspiration of the most suspicious axillary lymph node was performed.22 Sterile black carbon suspension (0.5 mL: 25 mg, Chongqing LUMMY Pharmaceutical Co) was injected in the cortex of the metastatic node under ultrasound guidance using a 25G needle by a trained ultrasonographer at the time of biopsy or during a separate session. The injection volume was recorded and varied depending on node size and operator. The trained ultrasonographer had more than 5 years of puncture experience. Of note, for the patients with multiple abnormal nodes or N3 disease under ultrasound at diagnosis, only the pathologically-proven lymph node is marked with carbon suspension.

Trial Locations (1)

350001

Study Officials, Fuzhou

All Listed Sponsors
lead

Fujian Medical University Union Hospital

OTHER

NCT07032220 - Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study | Biotech Hunter | Biotech Hunter